Nisa Investment Advisors
ACRS icon

Nisa Investment Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Nisa Investment Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19K Hold
318
– – ﹤0.01% 2715
2025
Q4 		$957 Hold
318
– – ﹤0.01% 2717
2025
Q3 		$604 Hold
318
– – ﹤0.01% 2824
2025
Q2 		$452 Hold
318
– – ﹤0.01% 2888
2025
Q1 		$487 Hold
318
– – ﹤0.01% 2802
2024
Q4 		$789 Hold
318
– – ﹤0.01% 2727
2024
Q3 		$366 Sell
318
-209
-40% -$256 ﹤0.01% 2772
2024
Q2 		$580 Buy
+527
New +$619 ﹤0.01% 2652
2023
Q4 		– Sell
-1,067
Closed -$7.31K – 2640
2023
Q3 		$7.31K Sell
1,067
-2,182
-67% -$18.6K ﹤0.01% 2230
2023
Q2 		$33.7K Buy
3,249
+2,802
+627% +$25.4K ﹤0.01% 1891
2023
Q1 		$4K Sell
447
-1,434
-76% -$18.2K ﹤0.01% 2252
2022
Q4 		$30K Hold
1,881
– – ﹤0.01% 1931
2022
Q3 		$29K Buy
1,881
+53
+3% +$835 ﹤0.01% 1936
2022
Q2 		$26K Buy
+1,828
New +$25.6K ﹤0.01% 1962

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Nisa Investment Advisors's ACRS Position: Q1 2026 in Review

Nisa Investment Advisors held its Aclaris Therapeutics (ACRS) position steady in Q1 2026 at 318 shares worth $1.19K. The position accounts for ﹤0.01% of the portfolio, ranked #2715.

Nisa Investment Advisors first reported a position in ACRS in Q2 2022 and has held it in 14 quarters since. The position peaked at $33.7K in Q2 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Nisa Investment Advisors held 318 shares of Aclaris Therapeutics worth $1.19K as of Q1 2026.
  • Nisa Investment Advisors left its Aclaris Therapeutics share count unchanged in Q1 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2715 holding.
  • Nisa Investment Advisors first reported a position in Aclaris Therapeutics in Q2 2022 and has held it in 14 quarters since.
  • Nisa Investment Advisors's Aclaris Therapeutics position peaked at $33.7K in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.